Avascular Necrosis Market Report 2026

The avascular necrosis market size has grown strongly in recent years. It will grow from $0.89 billion in 2025 to $0.97 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to trauma-related bone injuries, steroid overuse, alcohol consumption, delayed diagnosis, orthopedic surgery growth.

The avascular necrosis market size is expected to see strong growth in the next few years. It will grow to $1.38 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to advanced imaging adoption, regenerative medicine research, aging population, sports injury prevalence, orthopedic innovation. Major trends in the forecast period include rising use of early diagnostic imaging, increased adoption of joint-preserving therapies, growth of minimally invasive surgical procedures, expansion of physical rehabilitation programs, focus on early-stage disease intervention.

The growing number of knee replacements and hip surgeries is expected to drive the growth of the avascular necrosis market in the coming years. Knee replacements and hip surgeries are procedures performed to replace damaged joints and alleviate pain in severe cases of avascular necrosis. The demand for these surgeries is rising due to the increasing prevalence of osteoarthritis, which causes significant joint pain and mobility limitations, often necessitating surgical intervention to restore quality of life. Avascular necrosis contributes to this demand by causing bone tissue death due to reduced blood supply, leading to joint deterioration and collapse. For instance, in November 2024, the American Joint Replacement Registry (AJRR), a US-based registry managed by the American Academy of Orthopaedic Surgeons, reported that over 4 million hip and knee arthroplasty procedures were captured in 2023, marking an 18% increase compared to 2022. Therefore, the growing number of knee replacements and hip surgeries is fueling the growth of the avascular necrosis market.

Rising healthcare expenditure is also expected to drive the avascular necrosis market forward. Healthcare expenditure refers to the total spending on medical services, treatments, and healthcare products within a population or system. This expenditure is increasing due to the rising prevalence of chronic diseases, which require ongoing management, frequent hospital visits, and costly treatments. Higher healthcare spending supports the avascular necrosis market by enabling access to timely diagnosis, advanced therapies, and surgical procedures, improving patient outcomes. For example, in April 2025, the American Medical Association, a US-based professional association for physicians and medical students, reported that health spending in the United States grew by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per capita, surpassing the 4.6% increase seen in 2022.

In January 2024, Enovis Corporation, a US-based provider of medical technology and orthopedic surgical solutions, acquired LimaCorporate S.p.A. for approximately €800 million. Through this acquisition, Enovis gains access to LimaCorporate’s advanced joint-reconstruction implants, including 3D-printed trabecular titanium technology, and strengthens its presence in the shoulder and hip reconstruction segments. This enhances Enovis’s capabilities in reconstructive orthopedics, expands its global reach, and improves operational efficiency. LimaCorporate S.p.A., based in Italy, specializes in orthopedic implants and patient-specific digital and 3D-printed devices, recognized for its pioneering manufacturing expertise and innovative personalized reconstruction solutions.

Major companies operating in the avascular necrosis market are Stryker Corporation, Massachusetts General Hospital, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Stanford Health Care, Apollo Hospitals Enterprise Limited, Singapore General Hospital Pte Ltd., Fortis Healthcare Limited, Narayana Hrudayalaya Limited, Bumrungrad International Hospital Co. Ltd., Aster DM Healthcare Limited, Mount Elizabeth Hospital Pte Ltd., Gleneagles Hospital Pte Ltd., Shalby Limited, Texas Orthopedic Hospital LLC, Regrow Biosciences Pvt. Ltd., Maxcure Hospitals Limited, Medicover Hospitals Private Limited, Mesoblast Limited, Athersys Inc.

North America was the largest region in the avascular necrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the avascular necrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the avascular necrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised the cost of importing diagnostic equipment, surgical implants, and pharmaceutical products used in the avascular necrosis market, increasing overall treatment expenses. Surgical interventions, imaging-based diagnosis, and medication segments are most affected, especially in Asia-Pacific and North America due to dependence on imported medical devices and drugs. However, tariffs are encouraging localized production of orthopedic devices and generics, supporting more stable and cost-effective care delivery.

The avascular necrosis market research report is one of a series of new reports that provides avascular necrosis market statistics, including avascular necrosis industry global market size, regional shares, competitors with a avascular necrosis market share, detailed avascular necrosis market segments, market trends and opportunities, and any further data you may need to thrive in the avascular necrosis industry. This avascular necrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Avascular necrosis (AVN) is a medical condition in which bone tissue dies due to an insufficient blood supply. When blood flow to a bone is reduced or interrupted, bone cells begin to die, leading to the collapse of bone structure and eventual joint damage. AVN can result from trauma, long-term steroid use, excessive alcohol consumption, or certain medical conditions.

The main types of avascular necrosis are trauma-related AVN and non-trauma-related AVN. Trauma-related AVN occurs following a bone injury, such as a fracture or joint dislocation, which disrupts blood flow and causes bone tissue death. Diagnosis methods include imaging, biopsy, computed tomography (CT) scans, positron emission tomography (PET), and X-rays. Treatment options include medications, surgery, physical therapy, lifestyle modifications, and bone grafting. End-users of these treatments include hospitals, specialty clinics, rehabilitation centers, ambulatory surgical centers, and home care settings.

The avascular necrosis market consists of revenues earned by entities by providing services such as radiology services, pharmacotherapy management services, long-term preventive treatment, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The avascular necrosis market also includes sales of products, including bone graft materials, orthopedic implants, C1 esterase inhibitors, and platelet-rich plasma kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.